Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345–1356. doi: 10.1038/s41591-021-01450-2
   PubMed Web of Science ®Google Scholar
• Cooper AJ, Sequist LV, JJ L. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499–514. doi: 10.1038/s41571-022-00639-9
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. doi: 10.1016/S0140-6736(16)30958-8
   PubMed Web of Science ®Google Scholar
• Fukui T, Tachihara M, Nagano T, et al. Review of therapeutic strategies for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Cancers (Basel). 2022;14(5):1184. doi: 10.3390/cancers14051184
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415–453. doi: 10.1016/j.jmoldx.2013.03.001
   PubMed Web of Science ®Google Scholar
• Remon J, Pignataro D, Novello S, et al. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer. Cancer Treat Rev. 2021;95:102178. doi: 10.1016/j.ctrv.2021.102178
   PubMed Web of Science ®Google Scholar
• Golding B, Luu A, Jones R, et al. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):52. doi: 10.1186/s12943-018-0810-4
   PubMedGoogle Scholar
• Wang L, Wang W. Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (review). Oncol Rep. 2021;45:13–28. doi: 10.3892/or.2020.7851
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-Mutation-positive non–small-cell lung cancer. J Clin Oncol. 2018;36(22):2251–2258. doi: 10.1200/JCO.2017.77.4794
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi: 10.1056/NEJMoa1214886
   PubMed Web of Science ®Google Scholar
• Deeks ED. Ceritinib: A review in ALK-positive advanced NSCLC. Target Oncol. 2016;11(5):693–700. doi: 10.1007/s11523-016-0460-7
   PubMed Web of Science ®Google Scholar
• Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16(13):e510–e521. doi: 10.1016/S1470-2045(15)00013-3
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-Positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol. 2021;16(12):2091–2108. doi: 10.1016/j.jtho.2021.07.035
   PubMed Web of Science ®Google Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39. doi: 10.1016/S0140-6736(17)30565-2
   PubMed Web of Science ®Google Scholar
• Yun KM, Bazhenova LA. Update on lorlatinib: role in reducing the risk of disease progression in ALK-positive NSCLC. Cancer Manag Res. 2022;14:843–850. doi: 10.2147/CMAR.S283199
   PubMed Web of Science ®Google Scholar
• Tao Y, Zhou Y, Tang L, et al. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis. Invest New Drugs. 2022;40(4):831–840. doi: 10.1007/s10637-022-01242-6
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667. doi: 10.1016/S1470-2045(18)30649-1
   PubMed Web of Science ®Google Scholar
• Blackhall F, Ross Camidge D, Shaw AT, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2(3):e000219. doi: 10.1136/esmoopen-2017-000219
   PubMed Web of Science ®Google Scholar
• Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK -positive non–small-cell lung cancer. N Engl J Med. 2018;c379(21):2027–2039. doi: 10.1056/NEJMoa1810171
   Google Scholar
• Monzonís X, Arriola E. Early Onset Pulmonary Toxicity with Lorlatinib in a Patient with Previous Pulmonary Toxicity from Brigatinib. J Thorac Oncol. 2019;14(11):e247–e248. doi: 10.1016/j.jtho.2019.06.013
   PubMed Web of Science ®Google Scholar
• Pellegrino B, Facchinetti F, Bordi P, et al. Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clin Lung Cancer. 2018;19(2):e151–e161. doi: 10.1016/j.cllc.2017.10.008
   PubMed Web of Science ®Google Scholar
• Suh CH, Kim KW, Pyo J, et al. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. Lung Cancer. 2019;132:79–86. doi: 10.1016/j.lungcan.2019.04.015
   PubMed Web of Science ®Google Scholar
• FDA. FDA adverse event reporting system (FAERS) quarterly data extract Files [Internet]. Available from: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html
   Google Scholar
• ICH. Introductory Guide. MedDRA Version 25.1 [Internet]. Available from: https://www.meddra.org/
   Google Scholar
• ICH. Introductory guide for standardised MedDRA queries (SMQs) version 25.1 [Internet]. Available from: https://www.meddra.org
   Google Scholar
• Shu Y, Ding Y, Dai B, et al. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system. Expert Opin Drug Saf. 2022;21(4):563–572. doi: 10.1080/14740338.2022.2016696
   PubMed Web of Science ®Google Scholar
• Antoine M, Mlika M. Interstitial lung disease. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022;400(10354):769–786. doi: 10.1016/S0140-6736(22)01052-2
   PubMed Web of Science ®Google Scholar
• Skeoch S, Weatherley N, Swift AJ, et al. Drug-induced interstitial lung disease: A systematic review. J Clin Med. 2018;7(10):356. doi: 10.3390/jcm7100356
   PubMed Web of Science ®Google Scholar
• Conte P, Ascierto PA, Patelli G, et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open. 2022;7(2):100404. doi: 10.1016/j.esmoop.2022.100404
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. doi: 10.1200/JCO.2009.22.6993
   PubMed Web of Science ®Google Scholar
• GENENTECH_INC Food and Drug Administration Website. Alectinib (ALECENSA®) [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf
   Google Scholar
• NOVARTIS_PHARMACEUTICALS_CORP food and drug administration website. Ceritinib (ZYKADIA®) [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/205755s019lbl.pdf
   Google Scholar
• PFIZER_INC Food and Drug Administration Website. Crizotinib (XALKORI®) [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf
   Google Scholar
• PFIZER_INC Food and Drug Administration Website. Lorlatinib (LORBRENAL®) [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
   Google Scholar
• TAKEDA_PHARMACEUTICALS_INC Food and Drug Administration Website. Brigatinib (ALUNBRIG®) [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf
   Google Scholar
• Hwang A, Iskandar A, Dasanu CA. Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer. J Oncol Pharm Pract. 2019;25(6):1531–1533. doi: 10.1177/1078155218820580
   PubMed Web of Science ®Google Scholar
• Harada C, Kawaguchi T, Ogata-Suetsugu S, et al. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. Am J Respir Crit Care Med. 2011;183(6):743–751. doi: 10.1164/rccm.201002-0188OC
   PubMed Web of Science ®Google Scholar
• Gurule NJ, Heasley LE. Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses. Cancer Drug Resist. 2018;1:118–125. doi: 10.20517/cdr.2018.12
   PubMedGoogle Scholar
• Huang J, Zhao Y, Cao Y, et al. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS). Int J Clin Pharm. 2022;44(4):993–1003. doi: 10.1007/s11096-022-01425-4
   PubMed Web of Science ®Google Scholar
• Créquit P, Wislez M, Fleury Feith J, et al. Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: A retrospective observational cohort study with a systematic literature review. J Thorac Oncol. 2015;10(8):1148–1155. doi: 10.1097/JTO.0000000000000577
   PubMed Web of Science ®Google Scholar
• Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–2498. doi: 10.1200/JCO.2016.71.5904
   PubMed Web of Science ®Google Scholar
• Myall NJ, Lei AQ, Wakelee HA. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: A case series. Transl Lung Cancer Res. 2021;10(1):487–495. doi: 10.21037/tlcr-20-564
   PubMed Web of Science ®Google Scholar
• Huang JR, Chou CW, Chao HS. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease. J Oncol Pharm Pract. 2021;27(5):1311–1314. doi: 10.1177/1078155220961557
   PubMed Web of Science ®Google Scholar
• Kaira K, Naruse I, Shimizu K, et al. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib. J Cancer Res Ther. 2020;16(4):919–921. doi: 10.4103/jcrt.JCRT_985_15
   PubMed Web of Science ®Google Scholar